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Abstract
Background: The Cancer Atlas project has shown that p53 is the only commonly (96 %) mutated gene found in
high-grade serous epithelial ovarian cancer, the major histological subtype. Another general genetic change is
extensive aneuploidy caused by chromosomal numerical instability, which is thought to promote malignant
transformation. Conventionally, aneuploidy is thought to be the result of mitotic errors and chromosomal
nondisjunction during mitosis. Previously, we found that ovarian cancer cells often lost or reduced nuclear lamina
proteins lamin A/C, and suppression of lamin A/C in cultured ovarian epithelial cells leads to aneuploidy. Following
up, we investigated the mechanisms of lamin A/C-suppression in promoting aneuploidy and synergy with p53
inactivation.
Results: We found that suppression of lamin A/C by siRNA in human ovarian surface epithelial cells led to frequent
nuclear protrusions and formation of micronuclei. Lamin A/C-suppressed cells also often underwent mitotic failure
and furrow regression to form tetraploid cells, which frequently underwent aberrant multiple polar mitosis to form
aneuploid cells. In ovarian surface epithelial cells isolated from p53 null mice, transient suppression of lamin A/C
produced massive aneuploidy with complex karyotypes, and the cells formed malignant tumors when implanted in
mice.
Conclusions: Based on the results, we conclude that a nuclear envelope structural defect, such as the loss or
reduction of lamin A/C proteins, leads to aneuploidy by both the formation of tetraploid intermediates following
mitotic failure, and the reduction of chromosome (s) following nuclear budding and subsequent loss of
micronuclei. We suggest that the nuclear envelope defect, rather than chromosomal unequal distribution during
cytokinesis, is the main cause of aneuploidy in ovarian cancer development.
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Background
Recently, the Cancer Atlas project [1] determined that
mutation in p53 gene is the only common somatic gen-
etic change (96%) found in high-grade serous epithelial
ovarian cancer [1, 2], the most common histological sub-
type. However, inactivation of p53 in ovarian epithelial
cells in mouse models has not demonstrated a clear path
for epithelial tumorigenesis [3, 4], even in aged mice
following transplantation of p53 mutant ovaries [5].
Thus, the etiology and mechanism of epithelial ovarian
cancer is not yet satisfactorily understood.
Another common genetic change in ovarian carcin-
omas revealed from the cancer genomic study is exten-
sive aneuploidy [1]. The connection of abnormal
chromosomes with cancer was first recognized over one
hundred years ago by Boveri [6, 7]. Generally, aneu-
ploidy is thought to be the result of mitotic errors and
chromosomal nondisjunction during mitosis [8–10]. The
majority of human ovarian cancer cells are aneuploid
and possess a hyperdiploid (>46) to subtetraploid (<96)
chromosome number [11]. Although a correlation be-
tween aneuploidy and malignancy has been recognized,
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the causes and significance of aneuploidy in cancer re-
main unsettled [7, 12–17]. Several mechanisms have
been noted for the origination of aneuploidy [8, 10, 13,
18]. Genes that cause mitotic failure account for the ma-
jority of cases, and chromosomal non-disjunction is
thought to cause unequal distribution of chromosomes
in daughter cells [7, 10]. Tetraploid cells are believed to
form following mitotic failure, and aneuploid cells are
produced in subsequent mitotic events [8, 9, 13, 19].
Centrosome amplification also leads to multipolar cyto-
kinesis and aneuploidy [18].
One unique view is that chromosome instability and
aneuploidy may provide an unbalanced global expression
profile of increases and decreases in gene dosages that
create the cancer cell properties [12]. The general inter-
pretation is that chromosome instability and aneuploidy
promote the accelerated loss and gain of specific tumor
suppressor genes and oncogenes, respectively, leading to
selection of mutant cells with a growth advantage and
subsequent malignant transformation [14, 16, 19, 20].
Two possible routes, a progressive shift up pathway and
a tetraploid intermediate following drift down pathway,
may convert a diploid normal cell to an aneuploid can-
cer cell. Cells with an optimal chromosome composition
may have growth advantage, be selected, and become
neoplastic.
Enlarged and deformed nuclei are characteristics of
cancer cells, and the aberrant nuclear morphology corre-
lates with malignancy and is a diagnostic and prognostic
indicator, referred to as “nuclear grade” [21–26]. The in-
crease in chromosome number over normal cells ac-
counts for the larger nuclear size in cancer. Based purely
on the nuclear morphology of cells sampled, the PAP
test (or PAP smear), invented by Dr. Papanicolaou in the
1930s, is able to make diagnostic and prognostic predic-
tion of the degree of malignancy of uterine and cervical
cancers [27]. Changes in the nuclear matrix and/or nu-
clear envelope have been postulated, and deformation of
nuclear morphology was shown to associate with onco-
genic signaling [21, 28–31].
Shape of the nucleus is determined by structural pro-
teins of the nuclear envelope lamina, which has been
well studied [32–36]. Lamin A/C, but not lamin B1, is
critical for the maintenance of a smooth and oval shaped
nucleus [37]. Phosphorylation of lamin mediates revers-
ible disassembly and re-formation of nuclear envelope in
mitosis [38, 39]. Mutations or loss-of-function in several
nuclear envelope structure proteins, including emerin,
Man1, Baf, and lamin in C. elegans, cause similar nuclear
and mitotic phenotypes such as an enlarged and de-
formed nucleus, defective chromosome segregation, and
the formation of chromatin bridges between divided nu-
clei, suggesting a critical role for the nuclear envelope in
cytokinesis and mitosis [33, 34, 38–41]. However, lamin
A/C is dispensable for mitosis in mammalian cells since
deletion of lamin A/C does not impair development in
mice [42]. Nevertheless, lamin A/C is known to affect
mitosis [43, 44], and a role in nuclear envelope forma-
tion likely influences the process of cytokinesis, though
the redundancy of the three lamin genes present in
mammals may reduce the impact of a single gene. Thus,
roles of nuclear envelope proteins in maintaining the nu-
clear structure and mediating cytokinesis/mitosis are
conserved across species. Lamin A/C expression is ab-
sent in embryonic stem cells and early embryos, and is
progressively expressed in nearly all tissues in later de-
velopmental stages [45, 46]. The cell types that seem to
lack lamin A/C, such as embryonic carcinoma cells and
some cells of the spleen, thymus, bone marrow and in-
testine in the adult mouse, may fall into the “stem cell”
category [45, 46].
Loss or reduction of lamin A/C expression is often
found in cancer cells [47], including leukemia [48, 49],
colon [50], prostate [29], lung [51], breast [52], and gas-
tric cancers [53, 54]. Our earlier study also found that
lamin A/C expression is lost in about 60% of serous
ovarian carcinomas, in which the mRNA is often present
despite the loss of protein [55]. AKT and cell cycle
associated phosphorylation of lamin A/C lead to this
protein degradation [56–58]. One report concluded
that lamin A/C proteins are increased in ovarian can-
cer when normal ovarian tissues (instead of ovarian
surface epithelia) were used as controls [59]. However,
the ovarian epithelial cells of the surface layer were
found to be strongly positive, whereas the stromal
cells were largely low for lamin A/C [59]. Thus, the
correct interpretation of the result should be that 39% of
ovarian cancer cases are positive for lamin A/C, and lamin
A/C proteins are lost or greatly reduced in 61% of ovarian
cancers. Another report identified lamin C as a
marker that is reduced/lost in malignant ovarian can-
cer but not in borderline tumors based on results
from 2-dimensional gel electrophoresis [60]. Thus, the
published studies generally support our report that
lamin A/C proteins are lost in over half of ovarian
cancer. Previously, we found that suppression of
lamin A/C caused aneuploidy in human ovarian sur-
face epithelial cells [55]. Here, we further investigated
the mechanisms and consequences of the develop-
ment of aneuploidy and tumor development following
the loss of lamin A/C using both human and mouse
ovarian surface epithelial cells.
Results
Previously using siRNA to suppress lamin A/C expression
in human ovarian surface epithelial (HOSE) cells, we re-
ported that loss of lamin A/C proteins led to a deformed
nuclear morphology, polyploidy, and aneuploidy [55].
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Following up the previous findings, we explored the
mechanisms for the development of aneuploidy upon
lamin A/C suppression. The HOSE cells were transfected
with histone H2B-GFP that marks the nuclear DNA to
monitor the behavior of the cells in cultures, as described
previously [28]. Similar to that previously reported, about
50% of HOSE cells expressed GFP after transfection, and
the signals persisted for at the least 2 weeks over the
length of the experiments. We observed that at any given
time, 30 to 60% of the lamin A/C-suppressed HOSE cells
exhibited an aberrant nuclear morphology in about 200
cells analyzed. If allowed to follow the cells in cultures
over several hours, essentially all cells displayed some de-
gree of nuclear deformation, compared to about 5% in
controls that were transfected with scrambled siRNA
oligonucleotides.
One apparent feature of nuclear deformation was nu-
clear herniation, or budding (Fig. 1a, b). In around 20% of
over 200 cases examined, the nuclear body had an ex-
tremely extended herniation, and the nuclear materials
Fig. 1 Nuclear protrusion and herniation, mitotic failure, and aberrant cytokinesis in lamin A/C-suppressed HOSE cells. Lamin A and C were suppressed by
siRNA (Santa Cruz biotechnology Inc, Santa Cruz, CA) in primary human ovarian epithelial (HOSE) cells, using lipofectamine 2000 according to the
manufacturer protocol (Invitrogen, CA). a At day 3, the lamin A/C-suppressed cells were analyzed using immunofluorescence microscopy. An example of a
cell undergoing nuclear protrusion and herniation is shown (arrow), for nuclear staining with DAPI (blue) and lamin A/C (red). b The lamin A/C-suppressed
primary HOSE cells that were previously transfected with GFP-histone H2B were monitored for nuclear changes by time-lapse video fluorescence micros-
copy over a 48-h period. Time-lapse video microscopy was performed 12 h after lamin A/C suppression. Cells were seeded in 24 well falcon plate and
transfected the next day with scramble siRNA (control) or lamin A/C siRNA in serum reduced Opti-MEM media. Image acquisition was performed every 5
min for 48 h with a 40× dry objective lens on Nikon Eclipse TE 300 microscope linked to a Roper Scientific photometrics 12-bit range Camera using Meta
imaging series (MetaVue) software. Stacked images were assembled with MetaVue software to make the movies. Two examples of sequential time-lapse
images 15 min apart are shown. Arrows indicate the nuclear herniation and the formation of micronuclei, which gradually faded. Presumably, aneuploidy
was resulted in the remaining nuclei. c Sequential time-lapse images (images frame #1 to 12) 15 min apart are shown for a 3-h segment of a video of a
mitotic failure of a dividing cell. Arrows indicate the nuclei first underwent DNA condensation, separation, and then fused back to form presumably
tetraploid nuclei. d Sequential time-lapse images (frame #1 to 8) 15 min apart show an aberrant mitotic process. Arrows indicate the nuclei undergoing a
tripolar division. Likely, aneuploid cells were formed
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often broke off to produce a micronucleus (Fig. 1a, b).
When observed over a 6-h time-lapse, nearly all lamin A/
C-suppressed cells underwent nuclear herniation and re-
leased micronuclei, as shown in two examples (Fig. 1b).
Arrows indicate the nuclear protrusion and the formation
of micronuclei, which gradually faded, presumably being
degraded by the cellular proteolytic machinery. Conse-
quently, aneuploid cells resulted, containing the remaining
nuclei. In comparison, such phenomenon was rare in
lamin A/C-positive HOSE cells, and about 4% of over 200
control cells showed formation of micronuclei. Since
lamin A/C is frequently reduced or lost in ovarian cancer
cells [55], we reason that the lamin A/C-deficient ovarian
cancer cells may develop aneuploidy by such a mechan-
ism: nuclear protrusions and formation of micronuclei.
The observations that cancer cell often undergo transient
nuclear envelope rupture in gap phases [61] and collapse
of micronuclei produced [62] support this idea.
Another feature of Lamin A/C-suppressed HOSE cells
was frequent mitotic failure and the formation of tetra-
ploid cells (Fig. 1c). In the analysis of 48-h time-lapse
video, around a third (22 out of 80 mitotic events ob-
served) of mitosis in GFP-histone H2B-labeled, siRNA-
lamin A/C-transfected HOSE cells resulted in tetra-
ploidy, as an example shown (Fig. 1c). Typically in such
events, a cell was first observed to undergo nuclear con-
densation (Fig. 1c, frame #1–3) and subsequent attempt
in cytokinesis (Fig. 1c, frame #4–8). However, the form-
ing daughter nucleus failed to separate and then fused
(Fig. 1c, frame #9–11), and a presumed tetraploid cell
resulted (Fig. 1c, frame #12). In controls HOSE cells, mi-
totic failure was rare, none among 50 mitoses observed.
In mammalian cells that have 3 lamin genes (lmna en-
coding lamin A/C, lmnb1, and lmnb2), lamin A/C is not
essential for mitosis. However, lamin is essential for mi-
tosis in C. elegans, which has only one lamin gene [43].
Nevertheless, mutations in lamin A/C interfere with mi-
tosis and cell cycle progression in mammalian cells [43,
44]. Thus, our current finding that HOSE cells have an
increased rate of mitotic failure seems compatible with
the function of lamin proteins in cytokinesis during the
formation of daughter nuclei in the dividing cells.
Additionally, aberrant mitosis such as tripolar cell div-
ision was frequent in lamin A/C-suppressed cells, as an
example shown (Fig. 1d). The cells that underwent 3-way
mitosis generally had larger nuclei, suggesting that they
were tetrapoid cells, and thus aneuploid cells were gener-
ated. In the examination of 80 mitotic events of the lamin
A/C-suppressed, GFP-Histone H2B-labeled HOSE cells, 6
events of aberrant tripolar mitosis were recognized.
The analysis of the cell behavior following lamin A/C
suppression has been repeated over the course of 2 years,
and the results were consistent from 4 independent prepa-
rations of HOSE cells. The above results led us to suggest
that in lamin A/C-deficient cells, nuclear herniation to form
micronuclei, mitotic failure to form tetraploid, and tripolar
mitosis are mechanisms leading to the development of an-
euploidy. Previously we found that lamin A/C-suppressed
cells were not able to continue proliferation in culture,
likely because of aneuploidy and activation of p53 check
points [55].
We subsequently used primary mouse ovarian surface
epithelial (MOSE) cells to further investigate the mechan-
ism and consequence of lamin A/C-suppression. We rea-
soned that use of MOSE cells would allow us to introduce
p53 genetic mutation to mimic the genotype in human
ovarian cancer, and to bypass growth arrest following lamin
A/C suppression. Primary ovarian surface epithelial cells
were prepared from wildtype and p53 knockout mice, and
were transfected with scrambled (control) or lamin A/C
specific siRNA. The transfection efficiency ranged from 80
to 90% in various experiments based on uptake of labeled
cy3-siRNA oligonucleotides. Lamin A protein was signifi-
cantly reduced upon transfection with targeting siRNA as
visualized by Western blots (Fig. 2a). Using immunofluores-
cence microscopy, it was estimated that around 80% of the
MOSE cells had greatly reduced lamin A (Fig. 2b, c). Here,
a lamin A - specific antibody was used, since it was found
specific to the mouse protein, which is not properly recog-
nized by several other available lamin A/C antibodies
tested. The lamin A/C-suppressed MOSE cells also exhib-
ited frequent nuclear herniation, mitotic failure, and aber-
rant mitosis (Fig. 2b, c), similar to those observed in HOSE
cells upon suppression of lamin A/C expression.
We used flow cytometry to analyze cellular DNA content
of the cells following siRNA suppression of lamin A/C.
Comparing to the control cells (Fig. 2d) that have distinct-
ive G1 (2n) and G2 (4n) peaks, p53 (-/-) MOSE cells
showed a slightly higher fraction of polyploid (8n) cells
(Fig. 2e). The lamin A/C-siRNA suppressed cells had a dis-
tinctive profile (Fig. 2f): the G1 peak separated into two (or
more) main populations, which likely indicated the pres-
ence of a sub 2n fraction because of loss of one or few
chromosomes by nuclear protrusion and the formation of
micronuclei that was degraded. The G2 fraction was also
reduced in lamin A/C-suppressed cells, likely because a cell
cycle checkpoint was activated, as shown previously for
HOSE cells [55]. In the p53 null and lamin A/C-suppressed
cells, cell populations with various DNA content distributed
continuously from 2n to 8n, suggesting the development of
massive aneuploidy in these cells (Fig. 2g). Because of the
presence of extensive aneuploidy, the profiles of these flow
cytometry results were not suitable for analysis using a gen-
eral flow cytometry program that does not account for
aneuploidy.
Both the wildtype and the lamin A/C-suppressed
MOSE cells had only limited life span in culture, and be-
came senescent and deteriorated within 1–2 months.
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However, both the p53-deficient and the and the lamin
A/C-suppressed p53-deficient MOSE cells continued to
grow in culture. Following 4 weeks in culture, the ori-
ginal p53-deficient and Lamin A/C-suppressed MOSE
cells with a wildly variable distributed chromosome
number (Fig. 2g) converted into a more defined cellular
chromosomal number distribution (Fig. 2h). We inter-
pret that certain clones with optimal karyotypes from
the original populations had growth advantage in culture
and became the dominating cell populations.
Indeed, chromosome analysis of metaphase spreads in-
dicated aneuploidy and wide range of chromosomal
number distribution in the lamin A/C-suppressed p53-
deficient MOSE cells, such as 56, 60, 63, 67, 80, 81, 82,
84, 89, and 94 chromosomes, determined in 10 ran-
domly selected metaphase spreads. Two of the examples
are shown (Fig. 3a, b). Chromosome identification in
two samples revealed complex karyotypes in the lamin
A/C-suppressed p53-deficient MOSE cells (Fig. 3c, d),
and a marker chromosome was observed in one sample
(Fig. 3c). For comparison, metaphases from p53 knock-
out MOSE cells (without prior lamin A/C-siRNA treat-
ment) were found to be largely near diploid (40
chromosomes) to tetraploid (80 chromosomes), and
Fig. 2 Lamin A/C suppression in primary mouse ovarian surface epithelial (MOSE) cells results in aneuploidy and polyploidy, synergistic with p53
deletion. Primary wildtype (WT) and p53 knockout (KO) MOSE cells were transfected with control (scrambled) or siRNA (si-Lam A) to suppress
lamin A/C suppression. a At day 3, the lamin A/C-suppressed cells were analyzed by Western blot for the presence of lamin A protein. Duplicate
experiments are shown for control (scrambled siRNA) and siRNA specific to mouse lamin A/C. b The cells were analyzed by immunofluorescence
microscopy for the expression of lamin A. An example of p53 (-/-) MOSE cells treated with control siRNA is shown. c In comparison, staining was
reduced in cells treated with siRNA-lamin A/C. d Flow cytometry was performed 3 days after siRNA transfection. Cells were collected following
trypsin digestion, washed with PBS, and cell pellets were resuspended in ice cold ethanol/PBS (70% v/v) with gentle agitation. The fixed cells were kept
at − 20°C until ready to use. Prior to flow cytometric analysis, cells were centrifuged at 1200 rpm for 5 min and washed twice with PBS before
resuspension in 0.5 mm vybrant violet dye. Cells were then incubated at 37°C for 30 min before flow cytometric analysis for DNA content.
Flow cytometry profile for wildtype (WT) cells treated with control siRNA is shown. e p53 knockout cells; f WT cells treated with siRNA-lamin
A/C; g p53 knockout cells treated with siRNA-lamin A/C. h Flow cytometry profile of the p53 knockout, siRNA-lamin A/C-treated MOSE cells
following longer-term (2 months) culturing
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karyotyping by the cytogenetic core facility indicated
that obvious structural abnormalities were not observed,
but subtle abnormalities cannot be ruled out (quoted
from the facility report).
When the MOSE cells were implanted into nude mice,
both p53 (-/-) and lamin A/C-suppressed p53 (-/-)
MOSE cells were tumorigenic (Fig. 4). Tumors formed
in 5 of 6 nude mice when p53 (-/-) MOSE cells were im-
planted; and lamin A/C-suppressed p53 (-/-) MOSE cells
formed tumors in 6 out of 6 mice tested. The tumors de-
rived from the lamin A/C-suppressed p53 (-/-) MOSE
cells had unique malignant features (Fig. 4a): the tumor
cells often presented as small nodules invaded into
muscle fibers (Fig. 4b, c). The tumor cells also exhibited
a higher variation in nuclear sizes. In contrast, tumors
derived from p53 (-/-) MOSE cells grew as a single mass
with a more uniform nuclear morphology and size
(Fig. 4g, h). Thus, a transient suppression of lamin A/C
and generation of aneuploidy enable the growth of tu-
mors with an increased degree of malignancy. Neverthe-
less, when implanted into immune competent female
littermates from which the MOSE cells were prepared,
neither p53 (-/-) nor lamin A/C-suppressed p53 (-/-)
MOSE cells were able to produce significant or persist-
ent tumors, indicating these MOSE cells were unable to
escape the host immune surveillance in the development
of tumors.
When the tumors were analyzed by immunohisto-
chemistry, the tumors derived from lamin A/C-sup-
pressed p53 (-/-) MOSE cells showed lamin A/C
staining ranged from high (Fig. 4d), low (Fig. 4e), to
mixed (Fig. 4f ). Thus, it appears that some lamin A/C
expression was recovered following the prior transc1ent
suppression by siRNA. Interestingly, tumors derived
from p53 (-/-) MOSE cells uniformly had low lamin A/C
staining, in 3 out of 3 tumors analyzed as shown by a
representative example (Fig. 4i). Thus, unexpectedly, the
expression of lamin A/C is lower in tumors from p53
(-/-) MOSE cells without than with prior lamin A/C sup-
pression. The results suggest a preference in growth and
tumor development of a low laimin A/C cell population
in the p53 (-/-) MOSE cells. The idea that a reduced
lamin A/C expression may contribute to tumor develop-
ment following p53 inactivation will need to be further
verified.
Discussion
Previously, we found that lamin A/C expression is com-
monly lost in ovarian cancer, and suppression of lamin
A/C in ovarian surface epithelial cells led to the
Fig. 3 p53 inactivation and lamin A/C suppression result in aneuploidy and complex karyotypes. Primary p53 knockout MOSE cells were
transfected with control or siRNA (si-Lam A) to suppress lamin A/C expression. The cells were maintained and passaged for 2 months in culture,
and then subjected to chromosome analysis. Chromosome number counting and cytogenetic analysis were performed in 50 metaphase spreads
for each cell preparation. At least 10 chromosome spreads from each preparation were randomly selected and estimated for chromosome
number, and 2 appropriate samples were used for karyotyping. a and b, 2 representative examples of chromosome spreads from p53 (-/-) and
siRNA-lamin A/C-treated MOSE cells are shown. c and d, 2 examples of karyotyping from p53 (-/-) and siRNA-lamin A/C-treated cells are shown
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formation of aneuploidy, especially in p53 inactivated
cells [55]. In following up the previous finding, here we
determined the mechanisms for the development of an-
euploidy when lamin A/C is eliminated. We found that
when lamin A/C was suppressed, both the HOSE and
the MOSE cells often failed in completing cytokinesis,
and tetraploid cells were formed. Also, the aberrant nu-
clei underwent nuclear protrusion to form micronuclei,
presumably a mechanism for progressive reduction of
chromosome number to select for a growth permissive
karyotype (s). Indeed, we observed that the lamin A/C-
siRNA treated mouse p53 (-/-) MOSE cells exhibit com-
plex karyotypes that resemble those of ovarian cancer
cells.
The observation of frequent mitotic failure in lamin
A/C-depleted cells is consistent with the requirement of
lamin in cytokinesis in lower organisms such as C. ele-
gans and Drosophila [33, 34], which have only one lamin
gene. Possibly, the redundancy of the three lamin genes
in mammals is the reason that the absence of a single
lamin isoform would not generally cause cytokinesis fail-
ure, but rather increase the frequency of such events, as
we have observed here.
The experimental results described here support a hy-
pothesis that nuclear envelope defects (loss of lamin A/
C proteins) may be the common cause of chromosomal
numerical instability and aneuploidy in ovarian cancer
(Fig. 5a-c). The idea explains both nuclear morphological
deformation and aneuploidy, two prominent hallmarks
of ovarian cancer. Generally, chromosomal disjunction is
thought to be the cause of aneuploidy [7, 9, 10]. How-
ever, the results reported here leads us to a provocative
hypothesis that nuclear envelope defect, such as loss of
lamin A/C, rather than chromosomal disjunction
(Fig. 5a), may be the main cause of aneuploidy in ovarian
cancer (Fig. 5c). We reason that lamin A/C-deficient
cells frequently fail to complete cytokinesis. We specu-
late that this is cause by the failure to properly form new
nuclear envelope to encase the two new daughter nuclei,
and the dividing nucleus undergoes furrow regression to
produce tetraploid intermediates. Subsequently, aneu-
ploid cells are generated by tripolar division. Formation
of micronuclei at G-phases is another mechanism for
the loss of individual chromosomes [61–64].
Conclusions
Loss of lamin A/C appears to only increase the fre-
quency of such mitotic failure in mammalian cells,
though lamin is essential for cytokinesis in C. elegans,
which has only one lamin gene [40]. Aneuploid cells
Fig. 4 p53 inactivation and lamin A/C suppression lead to malignant tumors. Primary p53 knockout MOSE cells were transfected with control or
siRNA (si-Lam A) and cultured for about 2 months. When the lamin A/C-suppressed and p53 (-/-) MOSE cells were implanted in nude mice
subcutaneously, invasive tumors developed in 4 weeks (a). Two areas of the tumor are shown in higher magnification (b, c). Three examples of
tumors formed from lamin A/C-suppressed p53 (-/-) MOSE cells were stained with lamin A/C, as shown in (d), (e), and (f). g Tumors formed from
p53 (-/-) MOSE cells (not treated with lamin A/C-siRNA)) were compared, and a higher magnification (h) is shown. i An example of lamin A/C
immunostaining is shown for a tumor derived for p53 (-/-) MOSE cells
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may be growth retarded and undergo cell growth arrest or
death [65, 66]. p53 mutation may allow the cells to survive
and undergo clonal selection [67]. Most aneuploid cells
generated from transient loss of lamin A/C likely would
die, but ultimately, a population of cells with a unique
chromosomal composition is selected and expanded to
form cancer. Thus, our results advocate a concept that a
deformed nuclear envelope is the main source of chromo-
somal instability of the cancer cells, and is the cause rather
than a consequence of neoplastic transformation.
Methods
Reagents
Tissue culture flasks (Falcon), tissue culture media, trypsin,
and 100× antibiotic-antimycotic solution (Cellgro, Media-
tech, Inc) were purchased from Fisher Scientific Inc
(Springfield, NJ). Triazol reagent and transfection reagent
were purchased from Invitrogen Inc (Carlsbad, CA). For
Western blot detection, Super Signal West Dura Extended
Duration Substrate (PIERCE, Rockford, IL) was used. For
immunofluorescence microscopy, Alexa Fluor 488 and 596
conjugated secondary antibodies and Hoechst 33342
nuclear counter staining dye were purchased from Molecu-
lar Probes Inc (Eugene, Oregon). Primary antibodies, anti-
lamin A (H-102, rabbit polyclonal IgG), were purchased
from Santa Cruz Biotechnology Inc (Santa Cruz, CA).
Mouse models and xenograft tumor assay
The p53 knockout mice were purchased from Taconic
(Hudson, NY) [68]. The mouse colony was kept in the
C57BL/6 background and heterozygous pairs were bred
to produce homozygous or wild type mice, which were
used to prepare ovarian surface epithelial cells for exper-
iments. The mouse colony was maintained and geno-
typed as described previously [69, 70].
Immunodeficient Scid mice were purchased from Jackson
lab (Bar Harbor, ME). The mice were used for xenograft as-
says to test tumor development from MOSE cells by
implanting 5 × 106 cells subcutaneously in the immune de-
ficient nude mice. The cells were tested to ensure free of
microorganism contamination before xenograft assay. The
mice were monitored daily post implantation to observe
tumor development, up to 2 months. At the end of the ex-
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Fig. 5 Working model: nuclear envelope defect is the main cause of aneuploidy in carcinogenesis. a Depiction of normal cytokinesis: at the start
of M phase, the nuclear envelope dissolves, chromatin undergoes condensation, chromosomes pair and then separate, two new nuclear
envelopes form, and cytokinesis is completed. b Chromosomal Disjunction: during chromosomal separation, one or more chromosomes are not
attached. As a result, the two daughter cells have unequal distribution of chromosomes following cytokinesis. This mechanism is generally
thought to be the main cause of aneuploidy. c Nuclear envelope defect causes aneuploidy: We reason that loss of a nuclear envelope structural
component such as lamin A/C results in a misshapen nucleus. Additionally, the lamin A/C-deficient cells frequently fail to complete cytokinesis.
Thus, tetraploid cells and subsequently aneuploid cells are generated. Formation of micronuclei at G-phases is another mechanism for the loss of
individual chromosomes. Thus, we propose that the nuclear envelope defect is the main cause of aneuploidy in ovarian cancer development
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10% of body weight) were observed, the mice were eutha-
nized and the tumors were dissected and subjected to hist-
ology analysis.
Cell cultures
Primary human ovarian surface epithelial (HOSE)
were isolated and provided by Dr. Andrew K. Godwin
(Fox Chase Cancer Center). HOSE cells were cultured
in media containing 6 g/l of HEPES, 15% FBS, 1×
antibiotic-antimycotic, and insulin, as reported previ-
ously [55]. Ovarian cancer cells were cultured in
RPMI-1640 media supplemented with 10% FBS and
1× antibiotic-antimycotic. All cells were maintained at
37 °C in a humidified atmosphere of 5% CO2.
Primary mouse ovarian surface epithelial (MOSE) cells
were isolated from 2 to 3 ovaries of p53 (-/-) or wild
type BL6 mice of 3 to 6 months of age by collagenase di-
gestion for an hour, as described previously [69, 70]. The
cells released were harvested for culturing, and were
found to be more than 90% epithelial origin as charac-
terized by cytokeratin staining [70]. These primary cells
were used for experiments following a brief culture and
expansion of 4 to 7 days.
Small interfering RNA (siRNA) transfection
Lamin A/C expression in human cells (HOSE) was si-
lenced using siRNA reagent (Catalog # sc-35776) pur-
chased from Santa Cruz Biotech, Inc (Santa Cruz, CA).
siRNA specific for mouse lamin A/C (Lmna (ID 16905)
Trilencer-27 Mouse siRNA) was purchased from
OriGene Inc. The siRNA is a mixture of 3 to 5 RNA oli-
gonucleotides of 19–27 base long with sequences specif-
ically targeting human lamin A/C, as described
previously [55]. The siRNA oligonucleotides were trans-
fected into HOSE or MOSE cells using Lipofectamine
2000 according to the manufacturer’s protocol (Invitro-
gen, CA). Cells were analyzed 72 h after transfection for
Western blot and immunofluorescence microscopy ana-
lysis. Time-lapse video microscopy was performed 12 h
after lamin A/C suppression. Cells were seeded in 24
well Falcon plate and transfected the next day with
scrambled siRNA (control) or lamin A siRNA in serum
reduced Opti-MEM media. The media was changed 10
h after transfection with phenol red free filming media
containing 15% FBS, HEPES, glutamine and antibiotic
for ovarian epithelial cells. Time-lapse image acquisition
was performed every 5 min for 48 h with a 40× dry ob-
jective lens on Nikon Eclipse TE 300 microscope linked
to a Roper Scientific photometrics 12-bit range Camera.
Image acquisition was done using Meta imaging series
(MetaVue) software. Stacked images were assembled
with MetaVue software to make the movie.
Flow cytometric analysis
MOSE cells were seeded in T75 flasks and transfected the
next day with siRNA in serum reduced Opti-MEM media.
For fixed cells analysis, cells were re-suspended in ice-cold
ethanol/PBS (70% v/v) by gentle agitation. The fixed cells
were kept at − 20 °C until assayed. Prior to flow cytometric
analysis, cells were centrifuged at 1,200 rpm for 5 min and
washed twice with PBS before re-suspension in 0.5 mm
vybrant violet dye. Cells were then incubated at 37 °C for
30 min before flow cytometric analysis for DNA content,
as described previously [28, 55].
Immunofluorescence microscopy, time-lapse video, and
immunohistochemistry
Briefly for immunofluorescence microscopy, adhered cells
on 4-well chambered glasses were washed twice with PBS
at room temperature, fixed with 4% paraformaldehyde for
15 min, and permeablized with 0.5% Triton X-100 for 5
min. Then, the cells were washed three times with PBS,
blocked with 3% BSA in PBS containing 0.1% Tween-20
for 30 min, and incubated for 1 h at 37 °C with primary
antibodies that were diluted (1/200) in 1% BSA in PBS
containing 0.1% Tween- 20. AlexaFluor 488-conjugated
(green fluorescence) or AlexaFluor 594-conjugated (red
fluorescence) secondary antibodies were used. Nuclei and
chromosomes were stained with Hoechst 33342 solution
(1 M). Cells were washed three times, then mounted and
sealed in anti-fade reagent containing 100 mM of n-
propyl gallate (pH 7.4), 90% glycerol in PBS. Immuno-
fluorescence stainings were viewed with 60× or 100× oil
objective lens on Nikon Eclipse TE 300 microscope linked
to a Roper Scientific photometrics 12-bit range camera.
Image acquisition was done using Meta imaging series
(MetaVue) software. Images were merged using MetaVue
software.
For time-lapse video microscopy, the acquisition of
sequential image of cells expressing histone H2B-GFP
was made every 5 min for up to 24 h as described
previously [28].
Karyotyping and chromosome analysis
Chromosome number counting and cytogenetic analysis
were performed by the Cytogenetics & Molecular Diag-
nostic Laboratory of the University of Miami core facil-
ity. The cells were growth arrested at metaphase by
incubation with colcemid for 8 h. For each cell prepar-
ation, 50 metaphase spreads were obtained and sub-
jected to G-bands with 400 banding resolution. At least
10 chromosome spread samples from each preparation
were randomly selected and estimated for chromosome
number, and a few samples were used for chromosome
identification by an experienced cytogenetist and certi-
fied by the facility director.
Capo-chichi et al. BMC Cell Biology  (2016) 17:37 Page 9 of 11
Abbreviations
BSA: Bovine serum albumin; GFP: Green fluorescence protein; HOSE: Human
ovarian surface epithelial; MOPS: 3-Morpholinopropane-1-sulfonic acid, 3-(N-
Morpholino) propanesulfonic acid and 3-Morpholinopropanesulfonic acid;
MOSE: Mouse ovarian surface epithelial; PBS: Phosphate-buffered saline;
PMSF: Phenylmethylsulfonyl fluoride; SDS: Sodium dodecyl sulfate;
siRNA: Small interfering RNA; TBS: Tris-buffered saline; TBST: Tris-buffered
saline with Tween-20
Acknowledgement
Our lab alumni and students including Wensi Tao, Linlin Gao, Santas Rosario,
Ziqi Wang, Justin Correa, Jessica Clark, and Anthony Guerrero have worked
on this project and contributed to the basis of the current work. We also
thank our colleague Dr. Robert Moore for materials and technical advice in
the course of the experiments. We acknowledge the excellent technical
assistance from Flow Cytometry Core and Cytogenetic Core at the University
of Miami Miller School of Medicine. Primary HOSE cells were provided by the
lab of Dr. Andrew K. Godwin (Fox Chase Cancer Center). We thank our
colleagues, Drs. Sophia George and Robert Moore, for advice and discussion
during the course of the experiments and the preparation of the manuscript.
Funding
These studies were supported by funds from concept awards BC097189 and
BC076832 from Department of Defense (USA). Grants R01 CA095071, R01
CA099471, and CA79716 to X.X. Xu from NCI, NIH also contributed to the
studies. The work is also partially supported by a pilot grant from the
University of Miami cFAR grant P30AI073961 from NIH.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
CDC and XXX made the initial observation and conceived the main
hypothesis of the study. CDC performed the majority of the experiments
included in this manuscript, including cell culture study of expression by
Western blot, flow cytometry, immunofluorescence microscopy, and cell
growth assay. ERS contributed to cell culture and immunofluorescence
microscopy work. TMY assisted tumor and mouse model experiments. CDC
prepared the first draft of the manuscript, XXX made revisions, and all
authors were involved in editing and writing. All authors participated in
discussion and refining of the ideas and design of the experiments. All read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The protocols using mice for experiments were reviewed and approved by
the IACUC of the University of Miami Miller School of Medicine.
Author details
1Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida
33136, USA. 2Department of Cell Biology, University of Miami Miller School of
Medicine, Miami, FL 33136, USA. 3Institute of Biomedical Sciences, Laboratory
of Biochemistry and Molecular Biology, University of Abomey-Calavi, Abomey
Calavi, Benin.
Received: 4 October 2016 Accepted: 26 October 2016
References
1. Cancer Genome Atlas Research Network. Integrated genomic analyses of
ovarian carcinoma. Nature. 2011;474:609–15. Erratum in: Nature 2012; 490: 298.
2. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast Jr RC. The p53
tumor suppressor gene frequently is altered in gynecologic cancers. Am J
Obstet Gynecol. 1994;70:246–52.
3. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of
carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse
ovarian surface epithelium. Cancer Res. 2003;63:3459–63.
4. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction
of ovarian cancer by defined multiple genetic changes in a mouse model
system. Cancer Cell. 2002;1(1):53–62.
5. Chen CM, Chang JL, Behringer RR. Tumor formation in p53 mutant ovaries
transplanted into wild-type female hosts. Oncogene. 2004;23:7722–5.
6. Boveri T. Zur Frage der Enstehung maligner Tumoren. Jena: Gustav Fischer
Verlag; 1914.
7. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability,
aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 2009;10:478–4787.
8. King RW. When 2 + 2 = 5: the origins and fates of aneuploid and tetraploid
cells. Biochim Biophys Acta. 2008;1786:4–14.
9. Shi Q, King RW. Chromosome nondisjunction yields tetraploid rather than
aneuploid cells in human cell lines. Nature. 2005;437:1038–42.
10. Jefford CE, Irminger-Finger I. Mechanisms of chromosome instability in
cancers. Crit Rev Oncol Hematol. 2006;59:1–14.
11. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S,
Scudiero DA, Weinstein JN, Kirsch IR. Karyotypic complexity of the NCI-60
drug-screening panel. Cancer Res. 2003;63:8634–47.
12. Duesberg P. Does aneuploidy or mutation start cancer? Science. 2005;307:41.
13. Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer.
Curr Opin Genet Dev. 2007;17:157–62.
14. Micho F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal
instability initiate tumorigenesis? Semin Cancer Biol. 2005;15:43–9.
15. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature. 2004;432:338–41.
16. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability
and cancer. Nat Rev Mol Cell Biol. 2004;5:45–54.
17. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell
Biol. 2006;18:658–67.
18. Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat
Rev Cancer. 2007;7:911–24.
19. Margolis RL. Tetraploidy and tumor development. Cancer Cell. 2005;8:353–4.
20. Pihan G, Doxsey SJ. Mutations and aneuploidy: co-conspirators in cancer?
Cancer Cell. 2003;4:89–94.
21. Boyd J, Pienta KJ, Getzenberg RH, Coffey DS, Barrett JC. Preneoplastic
alterations in nuclear morphology that accompany loss of tumor suppressor
phenotype. J Natl Cancer Inst. 1991;83:862–6.
22. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev
Cancer. 2004;4:677–87.
23. Hsu CY, Kurman RJ, Vang R, Wang TL, Baak J, Shih IM. Nuclear size
distinguishes low- from high-grade ovarian serous carcinoma and predicts
outcome. Hum Pathol. 2005;36:1049–54.
24. Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP. The prognostic
value of nuclear morphometric analysis in serous ovarian carcinoma. Int J
Gynecol Cancer. 2008;18:692–701.
25. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison
of nuclear morphometry and Gleason grade as a predictor of prognosis in
stage A2 prostate cancer: a critical analysis. J Urol. 1989;142:1254–8.
26. Pienta KJ, Coffey DS. Correlation of nuclear morphometry with progression
of breast cancer. Cancer. 1991;68:2012–6.
27. Papanicolaou GN. A new procedure for staining vaginal smears. Science.
1942;95:438–9.
28. Capo-chichi CD, Cai KQ, Testa JR, Godwin AK, Xu XX. Loss of GATA6 leads to
nuclear deformation and aneuploidy in ovarian cancer. Mol Cell Biol. 2009;
29:4766–77.
29. Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, Tindall DJ.
p300 modulates nuclear morphology in prostate cancer. Cancer Res. 2005;
65:708–12.
30. Fischer AH, Taysavang P, Jhiang SM. Nuclear envelope irregularity is induced
by RET/PTC during interphase. Am J Pathol. 2003;163:1091–100.
31. Nickerson JA. Nuclear dreams: the malignant alteration of nuclear
architecture. J Cell Biochem. 1998;70:172–80.
32. Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker DK, Solimando L,
Goldman RD. Nuclear lamins: major factors in the structural organization
and function of the nucleus and chromatin. Genes Dev. 2008;22:832–53.
33. Gorjánácz M, Jaedicke A, Mattaj IW. What can Caenorhabditis elegans tell us
about the nuclear envelope? FEBS Lett. 2007;581:2794–801.
34. Margalit A, Liu J, Fridkin A, Wilson KL, Gruenbaum Y. A lamin-dependent
pathway that regulates nuclear organization, cell cycle progression and germ
cell development. Novartis Found Symp. 2005;264:231–40. discussion 240–5.
35. Wilson KL. The nuclear envelope, muscular dystrophy and gene expression.
Trends Cell Biol. 2000;10:125–9.
Capo-chichi et al. BMC Cell Biology  (2016) 17:37 Page 10 of 11
36. Wilson KL, Berk JM. The nuclear envelope at a glance. J Cell Sci. 2010;123:
1973–8.
37. Lammerding J, Fong LG, Ji JY, Reue K, Stewart CL, Young SG, Lee RT. Lamins
A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem. 2006;
281:25768–80.
38. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD, Li KM, Chau
PY, Chen DJ, Pei D, Pendas AM, Cadiñanos J, López-Otín C, Tse HF,
Hutchison C, Chen J, Cao Y, Cheah KS, Tryggvason K, Zhou Z. Genomic
instability in laminopathy-based premature aging. Nat Med. 2005;11:780–5.
39. Heald R, McKeon F. Mutations of phosphorylation sites in lamin A that
prevent nuclear lamina disassembly in mitosis. Cell. 1990;61:579–89.
40. Liu J, Rolef Ben-Shahar T, Riemer D, Treinin M, Spann P, Weber K, Fire A,
Gruenbaum Y. Essential roles for Caenorhabditis elegans lamin gene in
nuclear organization, cell cycle progression, and spatial organization of
nuclear pore complexes. Mol Biol Cell. 2000;11:3937–47.
41. Liu J, Lee KK, Segura-Totten M, Neufeld E, Wilson KL, Gruenbaum Y. MAN1
and emerin have overlapping function (s) essential for chromosome
segregation and cell division in Caenorhabditis elegans. Proc Natl Acad Sci
U S A. 2003;100:4598–603.
42. Sullivan T, Escalante-Alcalde D, Bhatt H, Anver M, Bhat N, Nagashima K,
Stewart CL, Burke B. Loss of A-type lamin expression compromises nuclear
envelope integrity leading to muscular dystrophy. J Cell Biol. 1999;147:913–20.
43. Cao K, Capell BC, Erdos MR, Djabali K, Collins FS. A lamin A protein isoform
overexpressed in Hutchinson-Gilford progeria syndrome interferes with
mitosis in progeria and normal cells. Proc Natl Acad Sci U S A. 2007;104:
4949–54.
44. Dechat T, Shimi T, Adam SA, Rusinol AE, Andres DA, Spielmann HP, Sinensky
MS, Goldman RD. Alterations in mitosis and cell cycle progression caused
by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci
U S A. 2007;104:955–60.
45. Lin F, Worman HJ. Expression of nuclear lamins in human tissues and
cancer cell lines and transcription from the promoters of the lamin A/C and
B1 genes. Exp Cell Res. 1997;236:378–84.
46. Röber RA, Weber K, Osborn M. Differential timing of nuclear lamin A/C
expression in the various organs of the mouse embryo and the young
animal: a developmental study. Development. 1989;105:365–78.
47. Foster CR, Przyborski SA, Wilson RG, Hutchison CJ. Lamins as cancer
biomarkers. Biochem Soc Trans. 2010;38:297–300.
48. Agrelo R, Setien F, Espada J, Artiga MJ, Rodriguez M, Pérez-Rosado A,
Sanchez-Aguilera A, Fraga MF, Piris MA, Esteller M. Inactivation of the lamin
A/C gene by CpG island promoter hypermethylation in hematologic
malignancies, and its association with poor survival in nodal diffuse large B-
cell lymphoma. J Clin Oncol. 2005;23:3940–7.
49. Stadelmann B, Khandjian E, Hirt A, Lüthy A, Weil R, Wagner HP. Repression
of nuclear lamin A and C gene expression in human acute lymphoblastic
leukemia and non-Hodgkin’s lymphoma cells. Leuk Res. 1990;14:815–21.
50. Willis ND, Cox TR, Rahman-Casañs SF, Smits K, Przyborski SA, van den Brandt
P, Van Engeland M, Weijenberg M, Wilson RG, De Bruïne A, Hutchison CJ.
Lamin A/C is a risk biomarker in colorectal cancer. PLoS ONE. 2008;3, e2988.
51. Machiels BM, Broers JL, Raymond Y, De Ley L, Kuijpers HJ, Caberg NE,
Ramaekers FC. Abnormal A-type lamin organization in a human lung
carcinoma cell line. Eur J Cell Biol. 1995;67:328–35.
52. Capo-chichi CD, Cai KQ, Smedberg J, Ganjei-Azar P, Godwin AK, Xu XX. Loss
of A-type lamin expression compromises nuclear envelope integrity in
breast cancer. Chin J Cancer. 2011;30:415–25.
53. Moss SF, Krivosheyev V, De Souza A, Chin K, Gaetz HP, Chaudhary N,
Worman HJ, Holt PR. Decreased and aberrant nuclear lamin expression in
gastrointestinal tract neoplasms. Gut. 1999;45:723–9.
54. Wu Z, Wu L, Weng D, Xu D, Geng J, Zhao F. Reduced expression of lamin
A/C correlates with poor histological differentiation and prognosis in
primary gastric carcinoma. J Exp Clin Cancer Res. 2009;28:8.
55. Capo-chichi CD, Cai KQ, Simpkins F, Ganjei-Azar P, Godwin AK, Xu XX.
Nuclear envelope structural defects cause chromosomal numerical
instability and aneuploidy in ovarian cancer. BMC Med. 2011;9:28.
56. Naeem AS, Zhu Y, Di WL, Marmiroli S, O’Shaughnessy RF. AKT1-mediated
Lamin A/C degradation is required for nuclear degradation and normal
epidermal terminal differentiation. Cell Death Differ. 2015;22:2123–32.
57. Kochin V, Shimi T, Torvaldson E, Adam SA, Goldman A, Pack CG, Melo-
Cardenas J, Imanishi SY, Goldman RD, Eriksson JE. Interphase
phosphorylation of lamin A. J Cell Sci. 2014;127:2683–96.
58. Bertacchini J, Beretti F, Cenni V, Guida M, Gibellini F, Mediani L, Marin O,
Maraldi NM, De Pol A, Lattanzi G, Cocco L, Marmiroli S. The protein kinase
Akt/PKB regulates both prelamin A degradation and Lmna gene expression.
FASEB J. 2013;27:2145–55.
59. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of
differentially expressed proteins in ovarian cancer using high-density
protein microarrays. Proc Natl Acad Sci U S A. 2007;104:17494–9.
60. Alaiya AA, Franzén B, Fujioka K, Moberger B, Schedvins K, Silfversvärd C,
Linder S, Auer G. Phenotypic analysis of ovarian carcinoma: polypeptide
expression in benign, borderline and malignant tumors. Int J Cancer. 1997;
73:678–83.
61. Vargas JD, Hatch EM, Anderson DJ, Hetzer MW. Transient nuclear envelope
rupturing during interphase in human cancer cells. Nucleus. 2012;3:88–100.
62. Hatch EM, Fischer AH, Deerinck TJ, Hetzer MW. Catastrophic nuclear
envelope collapse in cancer cell micronuclei. Cell. 2013;154:47–60.
63. Aristei C, Stracci F, Guerrieri P, Anselmo P, Armellini R, Rulli A, Barberini F,
Latini P, Menghini AR. Frequency of sister chromatid exchanges and
micronuclei monitored over time in patients with early-stage breast cancer:
results of an observational study. Cancer Genet Cytogenet. 2009;192:24–9.
64. Shimizu N, Itoh N, Utiyama H, Wahl GM. Selective entrapment of
extrachromosomally amplified DNA by nuclear budding and
micronucleation during S phase. J Cell Biol. 1998;140:1307–20.
65. Torres EM, Williams BR, Amon A. Aneuploidy: cells losing their balance.
Genetics. 2008;179:737–46.
66. Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE,
Amon A. Aneuploidy affects proliferation and spontaneous immortalization
in mammalian cells. Science. 2008;322:703–9.
67. Thompson SL, Compton DA. Proliferation of aneuploid human cells is
limited by a p53-dependent mechanism. J Cell Biol. 2010;188:369–1.
68. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT,
Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;
4:1–7.
69. Cai KQ, Wang Y, Smith ER, Smedberg JL, Yang DH, Yang WL, Xu XX. Global
deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-
deficient white spotting variant (Wv) mice. Neoplasia. 2015;17:89–100.
70. Wang Y, Cai KQ, Smith ER, Yeasky TM, Moore R, Ganjei-Azar P, Klein-Szanto
AJ, Godwin AK, Hamilton TC, Xu XX. Follicle Depletion Provides a Permissive
Environment for Ovarian Carcinogenesis. Mol Cell Biol. 2016;36:2418–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Capo-chichi et al. BMC Cell Biology  (2016) 17:37 Page 11 of 11
